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Strengths and limitations of this study
 ► The findings are from a unique and large popula-
tion-based cohort of patients diagnosed with a 
range of cancers with detailed characterisation of 
their presenting features.
 ► Diagnostic status (incidental or non-incidental) was 
identified using free-text information provided by 
healthcare professionals based on primary care 
records.
 ► We describe common mechanisms across different 
settings, and involving a range of tests and imag-
ing modalities, that led to an incidental diagnosis of 
cancer.
 ► We were unable to compare clinical outcomes be-
tween incidentally and non-incidentally diagnosed 
cancer patients.
ABSTRACT
Objectives Cancer can be diagnosed in the absence 
of tumour-related symptoms, but little is known about 
the frequency and circumstances preceding such 
diagnoses which occur outside participation in screening 
programmes. We aimed to examine incidentally diagnosed 
cancer among a cohort of cancer patients diagnosed in 
England.
Design Cross-sectional study of national primary care 
audit data on an incident cancer patient population.
Setting We analysed free-text information on the 
presenting features of cancer patients aged 15 or older 
included in the English National Audit of Cancer Diagnosis 
in Primary Care (2009–2010). Patients with screen-
detected cancers or prostate cancer were excluded. 
We examined the odds of incidental cancer diagnosis 
by patient characteristics and cancer site using logistic 
regression, and described clinical scenarios leading to 
incidental diagnosis.
Results Among the studied cancer patient population 
(n=13 810), 520 (4%) patients were diagnosed incidentally. 
The odds of incidental cancer diagnosis increased with 
age (p<0.001), with no difference between men and 
women after adjustment. Incidental diagnosis was most 
common among patients with leukaemia (23%), renal 
(13%) and thyroid cancer (12%), and least common 
among patients with brain (0.9%), oesophageal (0.5%) and 
cervical cancer (no cases diagnosed incidentally). Variation 
in odds of incidental diagnosis by cancer site remained 
after adjusting for age group and sex.
There was a range of clinical scenarios preceding 
incidental diagnoses in primary or secondary care. These 
included the monitoring or management of pre-existing 
conditions, routine testing before or after elective surgery, 
and the investigation of unrelated acute or new conditions.
Conclusions One in 25 patients with cancer in our 
population-based cohort were diagnosed incidentally, 
through different mechanisms across primary and 
secondary care settings. The epidemiological, clinical, 
psychological and economic implications of this 
phenomenon merit further investigation.
InTRODuCTIOn
Cancer is most often diagnosed following 
presentation with symptoms likely caused by 
the malignancy.1 2 However, some patients 
are diagnosed with cancer incidentally, in the 
absence of symptoms that could plausibly be 
related to the tumour and outside of formal 
cancer screening or surveillance activities. 
The use of imaging technologies (including 
X-ray, CT, MRI and PET scans) is a commonly 
described route to incidental diagnosis 
of different diseases, including cancer.3–6 
Chronic disease management involving 
periodic routine blood or urine testing are 
increasingly used in primary care and may 
represent another common pathway to inci-
dental diagnosis.7–10 Nonetheless, evidence 
regarding the frequency of such incidental 
diagnoses is currently limited.
Since incidental cancer diagnoses are char-
acterised by the absence of tumour related 
symptoms, it is plausible that this may repre-
sent overdiagnosis in some patients, whereby 
the detected cancer would not have other-
wise caused symptoms in the patient’s life-
time.11 Concerns about overdiagnosis thus far 
have largely focused on screening-detected 
cancers (eg, breast cancer), but it may be 
also occurring in other contexts.12 13 Ahead 
of considering the clinical, psychological or 
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economic consequences associated with incidental diag-
nosis (including the potential for overdiagnosis), we need 
to address gaps in knowledge about the frequency and 
characteristics of incidentally diagnosed cancer.
We therefore aimed to examine the frequency of inci-
dental diagnosis among an incident cohort of patients 
with cancer; compare the characteristics of incidentally 
versus non-incidentally diagnosed patients; and examine 
common pathways and mechanisms that led to the inci-
dental diagnosis of cancer using a unique data source 
relating to a national quality improvement initiative in 
England.
MeThODS
Study design and population
We analysed cross-sectional data collected as part of the 
English National Audit of Cancer Diagnosis in Primary 
Care (NACDPC).14 Briefly, health professionals from 
1170 participating general practices (representing 14% of 
practices in England) provided information on the diag-
nostic pathway for a consecutive sample of patients diag-
nosed with cancer during April 2009–2010. Participating 
practices were comparable to non-participating practices 
in (former) respective Cancer Networks, and the patient 
population was broadly representative of the contempo-
rary national incident cancer patient cohort.14 15 Unique 
to this audit, participating clinicians and other healthcare 
professionals provided information regarding the main 
presenting symptoms, cancer diagnosis, demographic 
characteristics and route of diagnosis for each patient 
based on primary care records.
Definition and identification of cases
The nature of cancer diagnosis (incidental or non-inci-
dental), was ascertained by examination of the free-text 
information included in the presenting symptoms data 
field (answering the audit question, ‘What were the main 
presenting symptom(s) [of the patient]?’).
Tumours were deemed to have been diagnosed inci-
dentally if the incidental nature of diagnosis was explic-
itly recorded by the participating healthcare professional 
(indicated by phrases including ‘accidental finding’, 
‘chance finding’, ‘incidental’, ‘opportunistic’), or if the 
clinical circumstances described were consistent with 
incidental identification based on clinical knowledge (GL 
and GPR) and prior literature.5 16 17 Cases were initially 
identified by MMK, and subsequently reviewed by GL and 
GPR; any disagreements were resolved by discussion.
Information was available on the patient’s sex, age 
group, and cancer site (categorised as bladder, brain, 
cervical, colorectal, endometrial, gallbladder, leukaemia 
(of any type), laryngeal, liver, lung, lymphoma, melanoma, 
mesothelioma, multiple myeloma, oesophageal, oropha-
ryngeal, ovarian, pancreatic, renal, sarcoma (of any type), 
small intestine, stomach, testicular, thyroid and vulval).14 
Patients diagnosed with prostate cancer were excluded 
a priori, given the difficulties in reliably distinguishing 
reasons for prostate specific antigen testing.18 Patients 
with screen-detected breast, colorectal and cervical cancer, 
and those diagnosed following surveillance for pre-malig-
nant or high-risk conditions were also excluded. There-
fore, the study population comprised 13 810 patients 
aged 15 or older with sufficient information to determine 
incidental/non-incidental status, and complete informa-
tion on cancer diagnosis, age group and sex (see online 
supplementary figure 1 for sample derivation).
Data analysis
First, we compared the demographic and clinical char-
acteristics of incidentally and non-incidentally diagnosed 
patients. Logistic regression was used to calculate crude 
and adjusted ORs of incidental diagnosis by sex, age 
group and cancer site. Male patients, and those aged 
60–69 years, were used as the reference category for sex 
and age group respectively, while colorectal cancer was 
used as the reference category for cancer site, as the 
most common non-sex specific cancer in our population. 
We also examined the cancer site case-mix (‘cancer site 
signature’) of the incidentally diagnosed group, that is, 
the relatively frequency of each cancer site among inci-
dentally diagnosed patients. All statistical analyses were 
conducted in STATA SE V.15 (StataCorp).
Subsequently, we identified common clinical scenarios 
leading to incidental diagnosis based on a subgroup of 
patients with sufficient information (n=345, 66% of all 
incidental diagnoses). These findings were synthesised 
narratively.
Sensitivity analysis
We performed sensitivity analyses expanding the defi-
nition of incidental diagnosis of cancer to include an 
additional 272 patients without any recorded presenting 
symptom, and/or with the presence of abnormal clin-
ical findings indicated in response to the audit question, 
‘What were the main presenting symptom(s) [of the 
patient]?’
Patient and public involvement
Patients and members of the public were not involved in 
the design of this study.
ReSulTS
Incidentally diagnosed cancer patients
A total of 520/13 810 (4%) patients aged 15+ years were 
diagnosed incidentally with one of 25 cancer sites (other 
than prostate cancer). Men were more likely to be diag-
nosed incidentally than women (5% of men vs 3% of 
women), although there was no evidence to support this 
after adjustment for age and cancer site (see table 1). The 
odds of being diagnosed incidentally with cancer gener-
ally increased with age (joint Wald test p value <0.001).
Crude and adjusted ORs indicated substantial varia-
tion in the odds of incidental diagnosis between cancer 
sites (see figure 1 and table 1). Almost a quarter (23%) 
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Table 1 Characteristics of incidentally vs non-incidentally diagnosed cancer patients, and crude/adjusted ORs of incidental 
status (n=13 810)
Total Incidental Crude Adjusted*
N n % (95% CI) OR (95% CI) OR (95% CI)
Total 13 810 520 4 (3 to 4) – –
Sex 0.001† 0.204†
  Men 5839 278 5 (4 to 5) Ref. Ref.
  Women 7971 242 3 (3 to 3) 0.63 (0.53 to 0.75) 0.88 (0.72 to 1.07)
Age group <0.001† <0.001†
  15–49 years 2072 31 1 (1 to 2) 0.40 (0.27 to 0.59) 0.39 (0.26 to 0.60)
  50–59 years 2050 65 3 (2 to 4) 0.86 (0.63 to 1.17) 0.88 (0.64 to 1.21)
  60–69 years 3181 117 4 (3 to 4) Ref. Ref.
  70–79 years 3656 170 5 (4 to 5) 1.28 (1.00 to 1.62) 1.28 (1.00 to 1.64)
  80+ years 2851 137 5 (4 to 6) 1.32 (1.03 to 1.70) 1.45 (1.12 to 1.89)
Cancer site <0.001† <0.001†
  Leukaemia‡ 450 103 23 (19 to 27) 10.49 (7.55 to 14.58) 11.84 (8.49 to 16.51)
  Renal 356 46 13 (10 to 17) 5.25 (3.53 to 7.78) 5.60 (3.77 to 8.33)
  Thyroid 110 13 12 (7 to 19) 4.74 (2.53 to 8.88) 7.25 (3.80 to 13.82)
  Liver 103 11 11 (6 to 18) 4.23 (2.16 to 8.27) 4.42 (2.24 to 8.68)
  Myeloma 228 20 9 (6 to 13) 3.40 (2.02 to 5.72) 3.39 (2.01 to 5.70)
  Gallbladder 68 5 7 (3 to 16) 2.81 (1.09 to 7.20) 2.96 (1.15 to 7.62)
  Mesothelioma 75 4 5 (2 to 13) 1.99 (0.71 to 5.61) 1.88 (0.66 to 5.31)
  Lymphoma 698 33 5 (3 to 7) 1.75 (1.14 to 2.69) 2.10 (1.37 to 3.23)
  Vulval 73 3 4 (1 to 11) 1.51 (0.46 to 4.94) 1.70 (0.52 to 5.60)
  Lung 1875 77 4 (3 to 5) 1.51 (1.08 to 2.12) 1.49 (1.07 to 2.09)
  Melanoma 834 30 4 (3 to 5) 1.32 (0.85 to 2.05) 1.69 (1.09 to 2.64)
  Bladder 842 28 3 (2 to 5) 1.22 (0.78 to 1.91) 1.16 (0.74 to 1.82)
  Colorectal 2399 66 3 (2 to 3) Ref. Ref.
  Stomach 302 8 3 (1 to 5) 0.96 (0.46 to 2.02) 0.94 (0.45 to 1.99)
  Ovarian 394 10 3 (1 to 5) 0.92 (0.47 to 1.81) 1.11 (0.56 to 2.20)
  Laryngeal 121 3 2 (1 to 7) 0.90 (0.28 to 2.90) 0.96 (0.30 to 3.12)
  Oropharyngeal 213 5 2 (1 to 5) 0.85 (0.34 to 2.13) 1.05 (0.42 to 2.64)
  Small Intestine 53 1 2 (0.3 to 10) 0.68 (0.09 to 4.99) 0.72 (0.10 to 5.28)
  Pancreatic 370 6 2 (1 to 3) 0.58 (0.25 to 1.35) 0.59 (0.26 to 1.38)
  Endometrial 410 6 1 (1 to 3) 0.52 (0.23 to 1.22) 0.61 (0.26 to 1.43)
  Testicular 149 2 1 (0.4 to 5) 0.48 (0.12 to 1.98) 1.05 (0.25 to 4.43)
  Breast 2675 34 1 (1 to 2) 0.46 (0.30 to 0.69) 0.59 (0.38 to 0.91)
  Sarcoma‡ 106 1 0.9 (0.2 to 5) 0.34 (0.05 to 2.45) 0.43 (0.06 to 3.14)
  Brain 215 2 0.9 (0.3 to 3) 0.33 (0.08 to 1.36) 0.37 (0.09 to 1.54)
  Oesophageal 566 3 0.5 (0.2 to 2) 0.19 (0.06 to 0.60) 0.19 (0.06 to 0.60)
  Cervical 125 0 0 (0 to 3) N/A N/A
*Adjusted for sex, age group and cancer site.
†Joint Wald test p value.
‡No information was available on leukaemia or sarcoma type.
N/A, not applicable.
of patients with leukaemia were diagnosed incidentally. 
More than one in ten patients with renal cancer (13%) 
thyroid (12%) and liver cancer (11%) were also diagnosed 
incidentally. In contrast, less than 1% of patients with 
sarcoma, brain, oesophageal and cervical cancers were 
diagnosed incidentally.
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Figure 1 ORs of incidental versus symptomatic diagnosis of cancer by cancer site (n=13 810; reference group: colorectal 
cancer). There is no OR for cervical cancer as there were no incidentally diagnosed cases of cervical cancer.
Figure 2 Commonly diagnosed cancer sites among the incidental cancer patient population; see online supplementary table 1 
for frequencies.
Among the 520 incidentally diagnosed patients, 
one-fifth (20%, 95% CI: 17% to 23%) were diagnosed with 
leukaemia, while other common cancer sites included 
lung (15%, 12% to 18%), colorectal (13%, 10% to 16%) 
and renal cancers (9%, 7% to 12%) (see figure 2 and 
online supplementary table 1). There were nine other 
cancer sites represented among the incidentally diag-
nosed patients each with 10 or more patients.
Sensitivity analyses (using a broader definition of 
incidental diagnosis) identified a further 272 cases, 
increasing the overall estimate of incidental diagnosis to 
6% (see online supplementary table 2 and online supple-
mentary figure 2). There was weak evidence to support 
greater odds of incidental diagnosis among men versus 
women (adjusted OR (95% CI): 0.84 (0.71 to 1.00)), with 
otherwise similar patterns of variation by age group and 
cancer site as those observed in the main analysis.
Routes to incidental cancer diagnosis
We identified several clinical scenarios preceding an inci-
dental diagnosis of cancer based on information avail-
able for 345 patients (66% of all incidentally diagnosed 
patients). These are outlined in table 2 and discussed in 
further detail below.
Many patients received an incidental cancer diagnosis 
as a result of a clinical encounter for a pre-existing chronic 
disease in primary or secondary care. This included 
routine blood or urine testing, as part of chronic disease 
(or related risk factor) management and monitoring, 
which revealed abnormalities that led to the diagnosis of 
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Table 2 Types of clinical scenarios preceding the incidental diagnosis of cancer
Clinical scenario Description and examples
Monitoring or managing pre-existing 
chronic morbidity
Blood or imaging investigations as part of monitoring or management of a chronic 
morbidity.
Eg, haematuria on dipstick urine testing [for diabetes] leading to diagnosis of 
bladder cancer.
Eg, annual blood tests for hypertension leading to diagnosis of leukaemia.
Before/after elective surgery for unrelated 
conditions
Blood or imaging investigations conducted before or after surgery, and more rarely, 
tumours identified in pathology specimens of tissue resected for other (benign) 
conditions.
Eg, pre-operative chest X-ray leading to diagnosis of lung cancer.
Eg, microscopic haematuria noted pre-cataract operation leading to diagnosis of a 
urological cancer.
Staging or follow-up for a previously 
diagnosed cancer
Blood or imaging investigations carried out as part of staging or follow-up for a 
previously diagnosed cancer.
Eg, scans to ascertain stage at diagnosis of prostate cancer leading to the diagnosis 
of another urological cancer.
Investigation of unrelated acute or new 
condition/symptoms
Blood or imaging investigations for a new or otherwise acute symptom or condition.
Eg, an abdominal ultrasound scan for dyspepsia leading to diagnosis of a urological 
cancer.
Eg, irregular mole noted during health check leading to diagnosis of melanoma.
otherwise unsuspected cancer. Some patients were diag-
nosed following blood or imaging investigations before/
after elective surgery for unrelated indications, with a 
small number of patients where tumours were seemingly 
identified in pathology specimens of tissue resected for 
non-malignant indications. A small number of patients 
were diagnosed after blood or imaging investigations 
carried out as part of staging or follow-up for a previously 
diagnosed cancer of a different site (eg, scans to ascertain 
stage at diagnosis of prostate cancer leading to the diag-
nosis of a renal cancer).
Other cancer patients were diagnosed following the 
investigation of unrelated acute conditions or presenting 
symptom(s) unlikely to be related to the subsequent 
cancer diagnosis. Some of these cases were being inves-
tigated for another suspected cancer (eg, a CT scan for 
a suspected pelvic cancer leading to the diagnosis of 
colorectal cancer) but for others, the diagnosis was more 
serendipitous (eg, breast lump found on examination for 
chest infection).
DISCuSSIOn
Principal findings
Around 1 in 25 patients with cancer in our study popula-
tion were diagnosed incidentally, with a preponderance 
of such cases among older patients, and patients with 
leukaemia, renal cancer, thyroid cancer, liver cancer 
and multiple myeloma. Clinical scenarios that preceded 
incidental diagnosis included healthcare encounters 
relating to previously known chronic conditions, and 
the investigation of acute or new conditions unrelated 
to cancer.
Strengths and limitations
Our study is based on a cohort of cancer patients (diag-
nosed 2009–2010) and is therefore limited by tempo-
rality of the data. However, thus far there have been no 
subsequent population-based data collections that could 
enable the detailed examination of the context of presen-
tation in patients subsequently diagnosed with cancer in 
England. Information on incidental status at diagnosis 
is not routinely recorded as part of cancer registration 
data, nor coded as such in administrative databases or 
patient experience surveys. A strength of our study is 
that it provides unique evidence about this less well docu-
mented diagnostic pathway of cancer, among a large and 
representative incident cohort characterised by health-
care professionals.
Nevertheless, interpretation of the findings should be 
mindful of the secondary nature of our analysis. Informa-
tion on symptoms (or their absence) was based on those 
recorded in primary care; patients found to be asymptom-
atic by healthcare professionals participating in the audit 
may have had symptoms that were not declared or not 
recorded during the consultation.19 20 In order to reduce 
the risk of the resulting bias on analyses, our definition of 
incidentally diagnosed cancer was deliberately conserva-
tive, designed to maximise specificity and reduce the likeli-
hood of patients being mistakenly identified as incidental 
diagnoses. However, this may have led to the under-esti-
mation of cases; our sensitivity analysis (based on a less 
conservative definition) indicates that an additional 2% 
of the study population may have been incidentally diag-
nosed (online supplementary table 2). Although the true 
estimates of incidental diagnosis may be higher than those 
reported, this is unlikely to have biased patterns of varia-
tion by cancer site and patient characteristics.
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Comparison with existing literature
Literature examining the prevalence of incidentally diag-
nosed cancer is limited, although some evidence may be 
gleaned from studies on incidental findings detected in 
the context of research studies. Estimates of clinically 
important incidental findings (including cancer but also 
other diseases) vary substantially depending on imaging 
field (whole body or specific organ) and modality 
however, and participants of research studies are unlikely 
to be representative of the cancer patient population.21 22
Though we were unable to examine potential overdi-
agnosis, we identified notable proportions of incidentally 
diagnosed patients with thyroid and renal cancer, and 
melanoma patients. This is consistent with prior evidence 
indicating potential overdiagnosis of these cancers.23–26 
A few studies have examined clinical scenarios that 
result in incidental diagnosis of individual cancer sites 
such as melanoma, lung cancer and renal cancer.17 27–29 
A study examining self-reported symptoms of haemato-
logical cancer patients found that a third of patients did 
not report any symptoms before diagnosis, with chronic 
lymphocytic leukaemia patients being particularly prone 
to being diagnosed incidentally, for example, through 
blood tests at routine healthcare encounters.30 Our find-
ings concord with these studies, but additionally show that 
incidental diagnosis occurs across a range of common 
and rarer cancers.
IMPlICATIOnS
Currently, there is sparse evidence regarding the preva-
lence or incidence of incidentally diagnosed cancer, likely 
due to the challenges in identifying such cases using large 
administrative healthcare data. Using unique data from 
an audit initiative, we were able to identify several clinical 
scenarios resulting in the incidental diagnosis of cancer. 
This study provides important epidemiological evidence 
quantifying the frequency of such cases, and character-
ising the different mechanisms that can lead to an inci-
dental cancer diagnosis.
Our findings indicate that a considerable number of 
cancer patients are diagnosed with cancer incidentally, 
without having presented with symptoms related to the 
subsequent diagnosis. An incidental cancer diagnosis 
could represent fortuitous early diagnosis of an invasive 
tumour, and therefore be of clinical benefit for a propor-
tion of patients. However, it could also represent overdi-
agnosis, which could lead to considerable psychological 
morbidity and unnecessary treatment.11
The frequency of incidental diagnosis, and the relative 
frequency of the scenarios preceding incidental diag-
nosis are likely to be affected by system level factors such 
as approaches to chronic disease monitoring, clinical 
incentives and thresholds for investigation, availability of 
imaging services and rates of elective surgery. 31 32 Given 
increasing levels of multi-morbidity and an ageing popu-
lation, there is progressively greater use of blood-based 
testing and imaging studies, which could lead to a greater 
proportion of patients being diagnosed incidentally, 
particularly for certain cancer types such as leukaemia.10 
Relatedly, incidental diagnosis of cancer occurred during 
investigation or follow-up of a pre-existing (unrelated) 
tumour in a small number of patients. As the survival of 
patients with cancer continues to improve, this could also 
become a more frequent route to incidental diagnosis.33 
Further examination of incidentally diagnosed cancer 
among more contemporary populations, and incidence 
trends of such diagnoses would be helpful in this regard, 
particularly given that some of these instances may repre-
sent overdiagnosis.
COnCluSIOnS
In conclusion, we have provided evidence about the 
frequency and common scenarios leading to incidental 
diagnosis of cancer. Our findings indicate that this is 
likely to be occurring in 1 in 25 patients with cancer and 
calls for further research establishing the prognostic, 
psychosocial and economic implications of incidentally 
diagnosed cancer.
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